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A B S T R A C T   
The DNA demethylating agent 5-aza-2′-deoxycytidine (DAC, decitabine) has anti-cancer therapeutic potential, 
but its clinical efficacy is hindered by DNA damage-related side effects and its use in solid tumours is debated. 
Here we describe how paracetamol augments the effects of DAC on cancer cell proliferation and differentiation, 
without enhancing DNA damage. Firstly, DAC specifically upregulates cyclooxygenase-2-prostaglandin E2 
pathway, inadvertently providing cancer cells with survival potential, while the addition of paracetamol offsets 
this effect. Secondly, in the presence of paracetamol, DAC treatment leads to glutathione depletion and finally to 
accumulation of ROS and/or mitochondrial superoxide, both of which have the potential to restrict tumour 
growth. The benefits of combined treatment are demonstrated here in head and neck squamous cell carcinoma 
(HNSCC) and acute myeloid leukaemia cell lines, further corroborated in a HNSCC xenograft mouse model and 
through mining of publicly available DAC and paracetamol responses. The sensitizing effect of paracetamol 
supplementation is specific to DAC but not its analogue 5-azacitidine. In summary, the addition of paracetamol 
could allow for DAC dose reduction, widening its clinical usability and providing a strong rationale for 
consideration in cancer therapy.   
1. Introduction 
Aberrant DNA methylation patterns are common in most cancers, 
arise early in tumour development and are potentially reversible by 
hypomethylating agents [1]. 5-aza-2′-deoxycytidine (Decitabine or 
DAC) is a nucleoside analogue that incorporates into replicating DNA in 
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place of cytosine where it traps and promotes the degradation of DNA 
methyltransferases (DNMTs) [2]. This results in two anti-cancer activ-
ities: methyl marks cannot be copied during DNA replication causing 
widespread DNA demethylation; and adducts are formed in the DNA 
leading to DNA damage and apoptosis [2]. DNA demethylating drugs are 
thought to de-repress epigenetically silenced tumour suppressor genes 
as well as demethylate endogenous retroviruses (ERVs), triggering an 
antiviral immune response and cancer cell death [2–4]. DAC has been 
approved by the European Medicines Agency (EMA) for treatment of 
acute myeloid leukaemia (AML) [5,6], while pre-clinical studies suggest 
it might also be effective in solid tumours [7]. However, the outcomes of 
clinical trials are highly variable, likely attributed to small sample sizes, 
lack of patient stratification, and inappropriate dosing and schedual [8]. 
Head and neck squamous cell carcinoma (HNSCC) originates from 
stratified squamous epithelium of the oral cavity and pharynx where the 
cells in the basal cell layer proliferate and replenish the suprabasal 
layers undergoing terminal differentiation [9]. HNSCC has a 5-year 
survival rate of ≤40%, highlighting a pressing need for new therapies 
[10]. Despite DNA methylation aberrations being common [11], the 
clinical evaluation of DAC potential in HNSCC is limited [12]. 
In solid tumours, DAC alone may not be curative, but favourable 
effects were observed when combined with other chemo- and immune- 
therapies [8]. However, it is not known whether the response to DAC 
could be enhanced by compounds not traditionally used in cancer 
treatment. In the current study, a custom-built library of 100 commonly 
used, cost-effective, off-patent drugs [13] was investigated for their 
ability to sensitize HNSCC cells to DAC treatment. Of the drugs tested, 
paracetamol was identified to work in synergy with DAC. 
Paracetamol (acetaminophen) is the most commonly used analgesic 
and antipyretic in both Europe and the United States [14]. Paracetamol 
affects the cyclooxygenase (COX) pathway wherein arachidonic acid 
(AA) is metabolized to prostaglandin H2 (PGH2) by either constitutively 
expressed COX-1 (PTGS1) or inducible COX-2 (PTGS2) [15]. PGH2 is 
then converted, by respective prostaglandin synthases, into effector 
prostanoids (prostaglandins PGE2, PGF2, PGI2 and PGD2 or thromboxane 
TXA) which work through metabolite-specific G-protein coupled re-
ceptors to activate downstream pathways [15]. 
The COX-2-PGE2 axis is associated with inflammation, growth and 
survival and is thought to contribute to the ‘inflammogenesis of cancer’ 
[16]. Increased expression of PTGS2 and production of PGE2 are found 
in many solid tumours, including HNSCC, and correlate with tumour 
stage, metastasis and worse clinical outcome, whilst low levels are 
associated with better response to chemotherapy [16,17]. Hence, COX-2 
inhibitors have been tested for their anti-cancer therapeutic activity 
activity and showed potential as preventative agents [17,18]. In estab-
lished tumours however, only overdose concentrations of paracetamol 
have demonstrated therapeutic potential [19–21]. 
Here we show that paracetamol can be used at clinically relevant 
concentrations to sensitize cancer cells (both HNSCC and AML) to DAC 
treatment, allowing for DAC dose-reduction. 
2. Materials and methods 
2.1. Cell lines and culture conditions 
Five human HNSCC cell lines were used: SCC040 (German Culture 
Collection, DSMZ (#ACC660)), FaDu (ATCC (HTB-43)), VU40T (Prof H. 
Joenje (VU University Medical Centre, Amsterdam)), HN12 (Dr J.F. 
Ensley (Wayne State University, Detroit, MI)) and UDSCC2 (Dr Henning 
Bier (University of Duesseldorf, Germany)). The cell lines were 
authenticated using STR profiling (NorthGene, UK). HNSCC cell lines 
were maintained in DMEM (Sigma- Aldrich) supplemented with 10% 
fetal bovine serum (FBS) (Sigma-Aldrich), 1% penicillin-streptomycin 
(Gibco), 4 mM L-glutamine (Sigma-Aldrich), 1X non-essential amino 
acids (Life Technologies) and 1 mM sodium pyruvate (Life Technolo-
gies). Primary human oral keratinocyte (HOK) cells were purchased 
from Caltag Medsystems and cultured over Poly-L-Lysine in Oral Kera-
tinocyte Medium supplemented with 1% oral keratinocyte growth sup-
plement (all from ScienceCell) and 1% penicillin-streptomycin. AML cell 
lines (SKM-1 (from Dr Stefan Heinrichs, University of Essen, Germany) 
and HL-60 (ATCC, CCL-240)) were cultured in RPMI1640 medium 
(ThermoFisher Scientific), supplemented with 15% FBS (Sigma- 
Aldrich), 1% L-glutamine and 1% penicillin-streptomycin. All cell lines 
were regularly tested for mycoplasma using MycoAlert (Lonza). 
2.2. Drugs treatments 
All drugs were purchased from Sigma-Aldrich. 5-Aza-2′-deoxy-
cytidine (DAC) was dissolved in either 50% acetic acid or in ≥99.9% 
dimethyl sulfoxide (DMSO); all other drugs, including azacitidine, were 
dissolved in DMSO. The treatments were carried out for 96h (HNSCC 
cells) or 72h (AML cells) using the relevant vehicle as a control. 
2.3. Viability assay 
Relative viability was determined in 96 well plates using the 
CellTiter-Blue Cell Viability Assay (Promega), including a minimum of 
triplicate wells per each sample and controls: vehicle, high concentra-
tion vehicle and ‘media only. Samples were normalized to a vehicle-only 
control. Sigma plot software (Systat Software Inc.) was used to generate 
sigmoidal, 4-parameter dose response curves after drug titrations. IC50 
values were calculated using MyCurveFit (MyAssays Ltd.). 
2.4. DAC sensitizing assay 
A panel of 100 drugs (Drug Library FMC1) were administered at the 
reported peak serum concentrations (Cmax) [13]. Cells were treated with 
each drug alone or in combination with 500 nM DAC. The assay was 
performed blind with controls hidden within the panel and viability 
assessed as above. 
2.5. Determining synergy 
The Chou-Talalay method was employed to determine synergy [22] 
using constant-ratio matched titrations (0.125X, 0.25X, 0.5X, 1X, 2X, 
3X, 4X, and 8X) of multiples of the Cmax (500 nM for DAC, 132 μM for 
paracetamol, 3 μM for azacitidine) and assessed by cell viability. The 
CompuSyn software [22] was used to calculate combination index (CI) 
and dose reduction index (DRI) values. 
2.6. Long treatment of AML cells 
SKM-1 and HL-60 cells were subjected to four cycles of 72h treat-
ments followed by 21 days withdrawal period (details in Supplementary 
Methods), the cells were counted at each passage using trypan blue 
(Sigma-Aldrich) staining and growth rates were calculated. 
2.7. DNA dot blotting 
DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen) 
and DNA dot blotting performed as described in Ref. [23] using a 
titration of DNA; detailed protocol and antibodies are provided in 
Supplementary Methods. Blots were normalized to methylene blue 
(Sigma-Aldrich) staining. 
2.8. Western Blot analysis 
Western Blot analysis was performed as described previously [13], 
with some alterations; protocol details and antibodies are provided in 
Supplementary Methods. 
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2.9. Giemsa-Jenner staining 
VU40T cells were grown on coverslips for 96h, fixed in methanol and 
stained with Giemsa and Jenner (VWR) as previously described [13]. 
SKM-1 cells were transferred to a glass slide with a Cytospin 3 (Thermo 
Shandon) before fixation. Microscope images were taken using EVOS XL 
Core Imaging System or BX-50 Olympus with a 100x oil immersion lens. 
2.10. Immunofluorescence analysis 
Immunofluorescence analysis was undertaken as described in 
Ref. [4] with details in Supplementary Methods. 
2.11. Apoptosis assay and cell cycle analysis 
Apoptosis and necrosis were assessed using the Annexin V Apoptosis 
Detection APC kit (eBioscience, ThermoFisher Scientific); details in 
Supplementary Methods. For cell cycle analysis, cells were fixed in 70% 
ice cold ethanol and resuspended in 200 μl 50 μg/ml propidium iodide 
solution (Sigma-Aldrich) and 50 μl of 100 μg/ml RNase solution 
(Roche). The solutions were analysed by flow cytometry on a Cyan B 
FACS analyser (Beckman Coulter). 
2.12. ELISA 
The levels of PGE2, Leukotriene B4 (LTB4) and Cysteinyl leukotrienes 
(LTC4, LTD4, and LTE4) were assessed in cell media using respective 
ELISA kits (Abcam). The results were normalized to the corresponding 
CellTiter-Blue viability results or cell count. 
2.13. Determining glutathione concentration 
The glutathione levels were measured using the GSH-Glo Gluta-
thione Assay (Promega) with 1 mM paracetamol used as a positive 
control. The results were normalized against the corresponding 
CellTiter-Blue cell viability or cell density. 
2.14. NAC rescue assay 
N-acely-L-cysteine (NAC, Sigma-Aldrich) was dissolved in water and 
neutralised using 1 M sodium hydroxide (Sigma-Aldrich). VU40T cells 
were treated with 2.5 mM NAC or an equivalent volume of vehicle for 
48h. Following this, wells were washed with fresh media and cells were 
treated with DAC, paracetamol or both for 96h and cell viability was 
determined. 
2.15. Assessment of reactive oxygen species (ROS) and mitochondrial 
superoxide (mitosox) 
MitoSOX Red (Cat# M36008, ThermoFisher Scientific) was used to 
assess mitosox, while ROS were measured using carboxy-H2DCFDA (5- 
(and-6)-carboxy-2′,7′-dichlorodihydrofluorescein diacetate, Cat# C369, 
Invitrogen); details in Supplementary Methods. 
2.16. Real-time quantitative PCR (qRT-PCR) 
Total RNA was extracted using RNeasy Mini Kit (Qiagen), including 
DNase I digestion step (RNase-Free DNase set, Qiagen). 1 μg of RNA was 
reverse transcribed (iScript cDNA Synthesis Kit (BioRad)) and the cDNA 
was purified with QiaQuick PCR Purification Kit (Qiagen). Purified 
cDNA was quantified using Qubit dsDNA High Sensitivity Assay kit 
(Thermo Fisher Scientific) to support normalization. qRT-PCRs were 
performed on a LightCycler 480 II using LightCycler 480 SYBR Green 
(Roche). Additional information and primers’ sequences are provided in 
Supplementary Methods and Supplementary Table S1. 
2.17. RNA sequencing 
For each sample, three biological RNA replicates were pooled to 
make a library using the TruSeq Stranded mRNA Library Prep kit and 
sequenced using a NextSeq 500 (Illumina) in paired-end mode at 2x75 
bases in the Genomics Birmingham facility (Birmingham, UK). Reads 
were aligned to the genome (hg19) using HiSAT2 and processed with 
bedtools to generate normalized coverage plots. Details on quantifica-
tion and data processing are in Supplementary Methods. 
2.18. Mouse xenograft study 
The mouse xenograft study was performed as described previously 
[24] and details of the protocol are in Supplementary Methods. To 
examine the toxicity and anti-tumour efficacy of DAC and paracetamol, 
we utilized male NOD/SCID/gamma (NSG) mice (Charles River) in 
accordance with the UK Home Office Animal (Scientific Procedures) Act 
1986 and approved by the local University of Birmingham Ethical Re-
view Committee. 24 males were implanted with 5 × 106 FaDu HNSCC 
cells suspended in serum-free medium and injected subcutaneously into 
the right flank. After three days the tumours established and mice were 
randomly allocated into four treatment groups on a 5 day on, 2 day off 
regimen: 0.4 mg/kg DAC in PBS via IP injection (or 0.2 mg/kg in the 
week three); 100 mg/kg paracetamol in PBS via oral gavage; DAC plus 
paracetamol as above; control (PBS) given both through the oral gavage 
and IP injection. Animals were monitored daily for signs of ill health and 
the tumours were measured. Upon culling, the tumours were excised 
and snap frozen for RNA extraction and subsequent analysis. 
2.19. Quantification and statistical analysis 
Statistical analysis and graphs were performed using GraphPad 
PRISM 8 software, unless stated otherwise. Details of the statistical tests 
used for each experiment are given in the corresponding figure legends. 
2.20. TCGA data 
Genetic alterations, gene expression and patient survival data were 
retrieved from The Cancer Genome Atlas (TCGA) via cBioPortal for 
Cancer Genomics [25]; the details are given in Supplementary Methods. 
2.21. Drug perturbation signatures 
Drug perturbation signatures were downloaded for the BROAD 
Connectivity Map dataset (CMAP) using the PharmacoGx package 
(version 1.14.0) [26] in R (details in Supplementary Methods). 
2.22. Drug Set Enrichment Analysis 
The effect of Decitabine, paracetamol, valdecoxib and azacitidine 
drug combinations on KEGG pathways and Gene Ontology Biological 
Processes was conducted using the Drug Set Enrichment Analysis 
(DSEA) server [27]. Significance of the perturbed pathways of interest 
was identified using the corresponding p-values per geneset; log10 
(p-values) were plotted as heatmaps. 
2.23. Data availability 
RNA-Seq data: The data are deposited at the GEO repository, 
accession number GSE110045 and SRA, accession number SRP132039. 
3. Results 
3.1. HNSCC cell lines show bimodal sensitivity to DAC treatment 
To establish the potential of DAC as a therapeutic in HNSCC, relative 
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cell viability was initially determined in four HNSCC cell lines and in 
normal human oral keratinocytes (HOK) after 96h of treatment 
(Fig. 1A). HOK cells showed no decrease in viability at clinically relevant 
concentrations (IC50 of 8.93 μM) while the four HNSCC cell lines could 
be divided into two groups; DAC-sensitive (VU40T, IC50 of 2.17 μM and 
HN12, IC50 of 0.81 μM) and DAC-resistant (SCC040, IC50 of 10.61 μM 
and UDSCC2, non-responsive) (Fig. 1A). This pattern was mirrored in 
the ability of DAC to demethylate DNA in the sensitive cell lines only 
(Fig. 1B), suggesting the efficacy of DAC treatment is proportional to its 
ability to demethylate DNA. 
3.2. Efficacy of DAC treatment can be synergistically increased with 
paracetamol 
In patients with AML, a 5-day regimen of 20 mg/m2 DAC gave a 
maximum plasma concentration (Cmax) of 107 ng/ml, equivalent to 469 
Fig. 1. DAC therapeutic potential in HNSCC cell lines can be synergistically increased by co-treatment with paracetamol. A. Dose dependent cell viability assay in 
response to 96h DAC treatment in four HNSCC cell lines and normal oral keratinocytes (HOK) shows a bimodal HNSCC response to DAC. Grey box indicates clinically 
relevant concentrations. DAC-sensitive cell lines are shown in reds, DAC-resistant – in greys, HOKs – in blue. B. Global levels of DNA methylation (5mC) were 
analysed by DNA dot blot in HNSCC cell lines ± 500 nM DAC, 96h and show the demethylating DAC effect in DAC-sensitive cell lines only. The data were normalized 
to methylene blue staining and an example of 5mC dot blot is shown below. For each replicate the results for 1 μg and 0.5 μg of DNA were averaged. C. Paracetamol 
shows the largest DAC sensitizing effect in VU40T cells among 100 off patent drugs (Drug Library FMC1) used in the assay. The cells were treated with 500 nM DAC 
with or without one of the drugs and the cell viability was compared to the drug only control. The scatterplot shows the DAC sensitizing effect of each drug while the 
full data are included in Supplementary Fig. S1. Y axis represents increase in sensitivity, grey area shows ± 2SD. D. Cell viability in four HNSCC cell lines and HOK 
cells treated for 96h with 132.3 μM paracetamol (Para), 601.7 μM valproic acid (VPA) and 323.4 μM zinc acetate (Zinc) ±500 nM DAC. Only DAC-sensitive cell lines, 
VU40T and HN12, can be sensitized to DAC treatment by paracetamol. Dotted lines show the effect of 500 nM DAC alone. E-G. DAC-paracetamol synergy was 
determined using Chou-Talalay method. Cell viability data for VU40T (E) and HN12 (F) cells treated with fixed titrations of DAC Cmax (500 nM), paracetamol Cmax 
(132 μM) or DAC + paracetamol were used to calculate combination index (CI) (G) and dose reduction index (DRI) (Supplementary Tables S2 and S3). CI < 1 
confirms synergistic interaction. In A-C and E-G n = 3, in D n = 3–7. In B statistical analysis was performed by paired two-tailed t tests. In D, for each cell line a 
matched One-Way ANOVA with Dunnett’s multiple comparison testing was used to compare DAC to DAC + drug. A separate paired t-test was applied to compare no 
treatment with DAC. Values are displayed as means ± SEM. Significant p values are shown. (For interpretation of the references to colour in this figure legend, the 
reader is referred to the Web version of this article.) 
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nM [6,28], while all HNSCC cell lines have an IC50 value greater than 
500 nM. Therefore, one sensitive (VU40T) and one resistant (SCC040) 
cell line were subjected to a DAC sensitizing screen to establish whether 
the efficacy of DAC could be increased (Fig. 1C, Supplementary Fig. S1). 
In the DAC-resistant SCC040 cells, none of the drugs were able to 
sensitize the cells to DAC (Supplementary Fig. S1A). However, in the 
DAC-sensitive VU40T cell line, paracetamol, valproic acid (VPA) and 
zinc acetate further decreased cell viability (Fig. 1C, Supplementary 
Fig. S1B). The paracetamol effect was replicated in the DAC-sensitive 
HN12 but not in DAC-resistant UDSCC2 cells (Fig. 1D). Importantly, 
paracetamol alone did not alter the viability of HOK cells (Fig. 1D). 
Therefore, DAC + paracetamol combination was further tested for 
synergy in VU40T and HN12 cells using the Chou-Talalay method [22]. 
Cell viability was assessed in response to each drug separately and in 
combination across eight constant-ratio matched titration of Cmax (500 
nM for DAC and 132 μM for paracetamol) (Fig. 1E–F). This analysis 
showed combination index (CI) values less than 1 at all bar the lowest 
concentration, demonstrating synergy (Fig. 1G). In VU40T cells, the 
dose reduction index (DRI) indicated that, when used in combination, 
each drug can be reduced 5-fold (Supplementary Table S2), allowing 
DAC dose reduction from 2.26 μM to the clinically relevant 450 nM. A 
similar reduction was observed for HN12 cells (Supplementary 
Table S3). 
3.3. Combined DAC + paracetamol treatment augments the effects of 
DAC on cell metabolism, proliferation and markers of basal epithelial cells 
It was next investigated whether the mechanisms underlying the 
DAC + paracetamol synergy involved reduced proliferation, altered cell 
cycle progression or increased cell death, possibly due to enhanced DNA 
damage. DAC is known to cause cell death and DNA damage [2]. As 
expected, in VU40T, 500 nM DAC increased both apoptosis and necrosis 
(Fig. 2A–B) as well as the number of nuclei with γH2AX foci (a marker of 
DNA damage and double strand breaks) when compared to control 
(Fig. 2C); however, these were not additionally enhanced by the addi-
tion of paracetamol (Fig. 2A–C). When compared to untreated cells none 
of the treatments resulted in change in cell cycle progression, however, 
the addition of paracetamol to DAC led to fewer cells progressing to 
G2/M phase than for DAC alone (Fig. 2D). Similarly, combined treat-
ment further decreased the number of Ki67-positive nuclei (a marker of 
proliferation) compared to DAC alone, whilst paracetamol alone had no 
effect (Fig. 2A, E). Markers for the basal cell layer (the only cell layer in 
healthy stratified epithelium that normally contains dividing cells), 
TP63 and keratin 5 (KRT5), were down-regulated by DAC in a 
dose-dependent manner and this was enhanced by the addition of 
paracetamol (Fig. 2F). Conversely, involucrin (IVL), a marker for 
differentiated, suprabasal layers was upregulated upon DAC (Fig. 2G). 
RNA sequencing of VU40T cells demonstrated substantial tran-
scriptome alterations following DAC treatment and this was signifi-
cantly enhanced by paracetamol (Fig. 2H). Six gene sets, up- and down- 
regulated by each treatment (Fig. 2H, Supplementary Table S4), were 
subjected to gene set enrichment analysis (Fig. 2I, Supplementary 
Table S5). Paracetamol treatment alone primarily resulted in up- 
regulation of genes involved in respiratory electron transport chain 
while the profile up-regulated by DAC was dominated by immune terms, 
especially interferon type I response. The latter was also evident in the 
combined treatment, although to a lesser extent. Interestingly, com-
bined treatment was enriched for terms related to tissue development 
and differentiation (including ‘pharyngeal system development’, Sup-
plementary Table S5). Genes down regulated by both DAC and DAC +
paracetamol showed similar ontology groupings related to DNA, protein 
and RNA metabolism and this enrichment was much stronger for the 
combined treatment (Fig. 2I). 
Therefore, although DAC alone has profound effects on proliferation, 
differentiation, cell death and DNA damage, the further reduction in 
viability observed in combined treatment is associated with a decrease 
in metabolism and proliferation, and divergence from the basal cell-like 
phenotype. 
3.4. DAC treatment enhances the cyclooxygenase pathway, which is offset 
by paracetamol 
Paracetamol is understood to act on the cyclooxygenase pathway 
(Supplementary Fig. S2A), mainly through inhibition of COX-2 (PTGS2) 
[15]. Transcriptional activation of the COX-2-PGE2 pathway by DAC was 
also evident in the RNA-seq data (Supplementary Fig. S2B), and a geneset 
for ‘Prostanoid biosynthetic process’ was enriched after both DAC and 
combined treatments (Supplementary Table S5). Therefore, the effect of 
DAC on this pathway was further examined. In DAC-sensitive VU40T cells 
but not DAC-resistant SCC040 cells, PTGS2 RNA and protein levels were 
upregulated by DAC and combined treatment (Fig. 3A and B). A corre-
sponding increase in the downstream product, prostaglandin E2 (PGE2) 
was observed after DAC treatment and returned to basal levels by the 
addition of paracetamol (Fig. 3C). This indicates that paracetamol can 
diminish DAC-induced COX-2 pathway activation. Additionally, expres-
sion of the PGE2 receptor PTGER1 increased in the DAC-sensitive VU40T 
cells whilst no significant changes in PTGER1-4 expression occurred in 
SCC040 (Fig. 3D, Supplementary Fig. S2C). The up-regulation of 
PTGS2 and PTGER1-2 can also be observed in HN12 cells; although the 
changes are less pronounced, they are highly consistent across DAC  
titrations (Supplementary Fig. S2D). There is a possibility that blocking 
the COX pathway could shunt AA towards the lipoxygenase (LOX) 
pathway, leading to increased survival potential [29]; however, we did 
not find evidence of this in DAC + paracetamol-treated HNSCC cells 
(Supplementary Fig. S3). In summary, DAC treatment specifically upre-
gulates many aspects of the COX-2-PGE2 pathway, inadvertently 
providing the cancer cells with growth and survival potential, while the 
addition of paracetamol offsets this effect (Fig. 3E). 
3.5. DAC treatment complements cancer-related activation of COX-2- 
PGE2 pathway 
Activation of the COX-2-PGE2 pathway has been previously indi-
cated in both HNSCC and other cancer types [16,17]. In the TCGA 
cohort, 29% of HNSCC tumours have at least one component of 
COX-2-PGE2 pathway transcriptionally activated, mostly PGE2 syn-
thases or PGE2 receptors (Fig. 3F). Similar activation can be observed in 
other cancers (Supplementary Table S6). However, over-expression of 
PTGS2 itself is relatively rare (2.3%), potentially serving as a limiting 
factor in the full pathway activation. Therefore, DAC-induced PTGS2 
up-regulation could remove this limitation and counteract the 
anti-tumour effects of DAC. PTGS2 up-regulation by DAC was also 
detected using Drug Perturbation Signatures (Fig. 3G) in the cMAP 
dataset [30], indicating the potential of DAC + paracetamol 
co-treatment could be applicable to other tumour types. 
3.6. Combined treatment depletes glutathione levels and increases 
oxidative stress in HNSCC cells 
If COX-2-PGE2 pathway alterations were solely responsible for DAC- 
paracetamol synergy, other COX inhibitors should have a similar effect. 
However, neither ibuprofen, nor the COX-2-specific inhibitor valdecoxib 
sensitized HNSCC cells to DAC treatment (Fig. 4A, Supplementary 
Fig. S4A-B). This was evident despite valdecoxib being able to reduce 
DAC-stimulated PGE2 synthesis comparably to paracetamol (Fig. 4B) 
and suggested an alternative mechanism. 
Previous work on the anti-cancer therapeutic potential of paraceta-
mol involved toxic doses, with efficacy attributed to an accumulation of 
the toxic metabolite of paracetamol, N-acetyl-p-benzoquinone-imine 
(NAPQI), resulting in glutathione depletion [19–21] (Fig. 4C). By 
comparison, our current work was performed using a safe concentration 
of paracetamol, 132 μM. However, in DAC-sensitive VU40T cells, DAC 
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Fig. 2. DAC-paracetamol combination enhances the effects of DAC on cell metabolism, proliferation and basal cell phenotype. A. Response of VU40T cells to 
paracetamol, DAC or both as indicated (representative images from 3 experiments). Left: Giemsa-Jenner staining (4x magnification); middle: Ki67 immunostaining; 
right: Annexin V and propidium iodine (PI) FACS analysis (healthy cells (bottom left); early apoptotic cells (bottom right); late apoptotic cells (top right) and necrotic 
cells (top left)). B. Proportion of VU40T cells undergoing cell death was assessed by FACS following Annexin V and PI staining (examples shown in (A)). The DAC- 
induced increase in cell death is not further enhanced by addition of paracetamol. C. Percentage of VU40T nuclei with indicated numbers of γH2AX foci following 
DAC, paracetamol and combined treatments. The DAC-triggered DNA damage is not enhanced by the addition of paracetamol. D. Cell cycle distribution in VU40T 
cells following 96h of indicated treatments and showing a slight increase in number of cells in G0/G1 phase following DAC + paracetamol treatment when compared 
to DAC alone. E. Addition of paracetamol to DAC treatment decreases proportion of nuclei positive for Ki67 immunostaining while paracetamol alone has no effect 
(examples in (A)). VU40T cells were treated as indicated for 96h. F. The expression of basal cell layer markers, TP63 and KRT5, is down-regulated by DAC in a dose 
dependent manner; this is enhanced in DAC + paracetamol treatment while paracetamol alone has no effect. qRT-PCR results are shown as normalized to ACTB in 
VU40T cells treated as indicated. G. The expression of involucrin (IVL, marker of differentiated keratinocytes) is up-regulated by DAC in a dose dependent manner 
and this was more pronounced after addition of paracetamol. qRT-PCR results are shown as in (F). H. RNA-seq was performed in VU40T cells after 96h of DAC, 
paracetamol and DAC + paracetamol treatments. Venn diagrams show overlap for the most upregulated (left, log2 fold change ≥1) and down-regulated (right, log2 
fold change ≤ -1) genes when compared to vehicle control. The number of genes affected by combined treatment is much higher than for DAC alone. Paracetamol 
treatment only moderately affects the cells’ transcriptome. I. Six gene sets (up-regulated or down-regulated by DAC, paracetamol and combined treatment) were 
analysed for enrichment of GO-Biological Processes pathways, further consolidated using REVIGO. Paracetamol treatment alone resulted in no significant enrichment 
for down-regulated gene sets. Top 5 terms from the remaining five groups are combined and included in the heatmap. Category scores are shown as log10 p-value. 
Unless stated otherwise all treatments were for 96h with 500 nM DAC and 132.2 μM paracetamol. In B-D and F-G n = 3, in E n = 6. In B and D: Two-Way ANOVA with 
Dunnett’s correction was preformed to compare Ctrl with treatments and a separate Two-Way ANOVA with Sidak’s was performed to compare DAC with combined 
treatment. In C: matched Two-Way ANOVA with Tukey’s multiple comparison test was used to compare the distribution of foci number between each treatment 
group. In E-G: matched One-Way ANOVA with Dunnett’s multiple comparison test was used to compare all treatments to Ctrl. A separate paired two-tailed t-test was 
used to compare DAC to DAC + paracetamol. Values are displayed as means ± SEM. 
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treatment caused an up-regulation of the majority of CYP 
enzymes-encoding genes (Supplementary Fig. S5A), including CYP2E1, 
thought to be primarily involved in the conversion of paracetamol into 
NAPQI (Fig. 4D–E). Assessing NAPQI levels is unreliable due to its highly 
reactive nature [31]. However, combined treatment led to a major 
reduction in GSH levels, a surrogate marker often used, and the effect 
was equivalent to high dose (1 mM) paracetamol (Fig. 4F). Furthermore, 
48h pre-treatment with 2.5 mM N-acetyl cysteine (NAC, used clinically 
as an antidote to paracetamol overdose [19]) restored the viability of 
DAC + paracetamol treated cells to control level (Fig. 4G). Therefore, 
the combined treatment leads to the depletion of GSH stores in tumour 
cells, even at a clinically safe paracetamol concentration. 
GSH is an intracellular antioxidant that acts as a reactive oxygen 
species (ROS) scavenger [32]. In agreement with this, DAC + paracet-
amol co-treatment significantly increased both intracellular ROS 
(Fig. 4H) and mitochondrial superoxide (Fig. 4I) when compared to DAC 
alone. This was specific for DAC + paracetamol and not DAC + valde-
coxib (Fig. 4H–I). The effects of combined treatment on GSH, ROS and 
Fig. 3. DAC treatment specifically activates COX-2-PGE2 pathway in DAC-sensitive cells. A. qRT-PCR for PTGS2 shows increase in gene expression upon both DAC 
and DAC + paracetamol treatments in DAC-sensitive VU40T cells but not in DAC-resistant SCC040. The 96h treatments were performed as indicated. Results are 
normalized to cDNA concentration. B. PTGS2 protein levels are also up-regulated in VU40T but not in SCC040 cells. Graph represents the data from three experiments 
normalized to Lamin A/C. C. PGE2 concentration was assessed by ELISA in media collected from VU40T and SCC040 cells treated for 96h as indicated. The data are 
normalized to cell viability and show induction of PGE2 synthesis by DAC in DAC-sensitive VU40T cells only while the addition of paracetamol reverses this effect. D. 
qRT-PCR for PGE2 receptor, PTGER1, shown as in (A). DAC treatment, either alone or in combination with paracetamol, leads to an increase in PTGER1 expression in 
VU40T cells while neither PTGER1 nor PTGER2-4 (Supplementary Fig. S2C) are up-regulated in DAC-resistant SCC040 cell line. E. Schematic of COX-2-PGE2 pathway 
with confirmed DAC effects shown in red. COX-2 catalyzes the conversion of arachidonic acid into prostaglandin H2. This is then converted into prostaglandin E2 
which exerts its effects through G-protein coupled receptors. In this model DAC affects gene expression levels while paracetamol blocks protein function. The full 
COX-2 pathway is shown in Supplementary Fig. S2A. F. COX-2-PGE2 pathway-related gene expression across 522 HNSCC tumour samples indicates 150 (29%) of 
tumours have at least one of the genes up-regulated. However, PTGS2 up-regulation is rare. Heatmap was created in cBioPortal based on provisional HNSCC cohort 
(TCGA). % indicates fraction of tumours with alterations for each of the genes. G. Expression of PTGS2, as well as PTGER2 and PTGER4, is strongly up-regulated by 
DAC treatment in five cancer cell lines included in the BROAD Connectivity Map (CMAP) dataset which consists of transcriptional profiles following treatments with 
1309 different drugs. Heatmap shows Drug Perturbation Signature for genes of the COX-2-PGE2 pathway for Decitabine (DAC) and paracetamol (Para). A-D: all 
treatments were for 96h with 500 nM DAC and 132.2 μM paracetamol and performed in three biological replicates. In A, B and D: for each cell line a matched One- 
Way ANOVA with Dunnett’s multiple comparison test was used to compare all treatments to Ctrl; a separate paired two-tailed t-test was used to compare DAC to DAC 
+ paracetamol. In C: for each cell line an ordinary One-Way ANOVA with Sidak’s correction was applied to compare treated groups with Ctrl. Values are displayed as 
means ± SEM. Only significant p-values are shown. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of 
this article.) 
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mitochondrial superoxide levels were also observed in HN12 cells 
(Supplementary Fig. S5B-E). Accumulation of ROS triggers an 
anti-oxidant response which can protect cancer cells treated with che-
motherapeutics [33]. However, the RNA-seq data for VU40T cells 
showed the majority of genes described as direct anti-oxidant re-
sponders [34] to be down-regulated upon both DAC and DAC + para-
cetamol (Fig. 4J), potentially exacerbating oxidative stress. Finally, it 
has been shown that keratinocytes can tolerate GSH depletion as long as 
the cysteine pools and the thioredoxin reductase system (TXN/TXNRD) 
are functional [35]. Again, DAC down-regulated most of these genes in 
VU40T cells (Fig. 4K). 
To summarize, in cancer cells, DAC-paracetamol co-treatment 
mimics the mechanisms of paracetamol overdose (Fig. 4L), whilst cell 
adaptation to oxidative stress could be impaired by DAC, therefore 
improving the efficacy of anti-cancer drugs [36]. 
The specificity of the DAC-paracetamol interaction is further sup-
ported through Drug Set Enrichment Analysis (DSEA) [27] which 
identified that DAC and paracetamol share significant enrichment not 
only for COX, cytochrome P450 and GSH metabolism pathways, but also 
for keratinocyte differentiation. Such common enrichment was not 
observed for DAC and valdecoxib combination (Fig. 4M, Supplementary 
Fig. S6). Importantly, the expression of gene sets identified behind the 
DAC and paracetamol interaction (namely, suppression of 
DAC-activated COX-2-PGE2 pathway, depletion of the GSH stores and 
thioredoxin response) significantly affects survival in HNSCC (Fig. 4N 
and Supplementary Table S6) and other cancers (Supplementary 
Table S7) in TCGA data sets. This confirms that the DAC + paracetamol 
combination targets pathways and genes of clinical importance. 
3.7. In vivo potential of DAC + paracetamol combination treatment 
To assess the DAC + paracetamol treatment in vivo, we utilized an 
NSG mouse xenograft model using human HNSCC FaDu cells [24]. FaDu 
cells were first confirmed in vitro to respond synergistically to 
DAC-paracetamol co-treatment (Fig. 5A–B). Similar to what was 
observed in VU40T cells, DAC treatment up-regulated expression of 
PTGS2 and PTGER1-2 (Fig. 5C). In addition, CYP2E1 expression 
increased significantly upon DAC treatment (Fig. 5C) while combined 
treatment led to enhanced GSH depletion (Fig. 5D) and mitochondrial 
superoxide accumulation (Fig. 5E). The thioredoxin and anti-oxidant 
response genes were also slightly down-regulated (Supplementary 
Fig. S7). In further agreement with the VU40T data the DAC-imposed 
down-regulation of basal cell marker KRT5 was significantly enhanced 
by the combined treatment (Fig. 5F). 
Mice were injected in the right flank and the treatments (DAC, 
paracetamol, DAC + paracetamol or vehicle (PBS)) were administered 5 
days a week (Fig. 5G). After the first two weeks, tumours in the control 
and paracetamol-treated groups reached the maximum permissible size, 
while DAC alone and DAC + paracetamol groups were treated for 
another week (Fig. 5G). Due to the strong initial response to DAC, the 
concentration was reduced (0.2 mg/kg) for the final week. Although 
DAC alone showed a strong anti-tumour effect, the DAC + paracetamol- 
treated tumours remained consistently smaller throughout the treat-
ment, no tumours exceeded 300 mm3 and 5/6 animals survived until the 
end of the experiment (Fig. 5G–H). Furthermore, the gene expression 
alterations in tumour tissues were consistent with the in vitro observa-
tions: upregulation of PTGS2 and CYP2E1 (Fig. 5I) and down-regulation 
of TP63 and KRT5 (Fig. 5J). In summary, the in vivo data support the 
potential use of DAC in the treatment of DAC-sensitive HNSCC tumours. 
They also suggest paracetamol could increase DAC efficacy, however, 
Fig. 4. Combined DAC-paracetamol treatment mimics the effects of paracetamol overdose, depletes glutathione levels and leads to oxidative stress. A. Cell viability 
in VU40T cells treated for 96h with 132.3 μM paracetamol, 10 μM valdecoxib or 193.9 μM ibuprofen ± 500 nM DAC. Neither ibuprofen nor valdecoxib treatment 
could reproduce the DAC-sensitizing effect observed for paracetamol, indicating the effect is paracetamol-specific. Dotted line shows the effect of DAC alone. B. PGE2 
concentration in the media of VU40T cells treated with DAC with or without paracetamol or valdecoxib shown as relative to either vehicle control (left) or DAC only 
treatment control (right). Valdecoxib blocked PGE2 synthesis in both DAC-treated and untreated cells, comparably to paracetamol, suggesting synergistic effects act 
outside of the COX2-PGE2 pathway. C. Schematic of paracetamol overdose. A fraction of paracetamol is converted into the toxic metabolite NAPQI, and detoxified by 
GSH. However, when paracetamol is taken in excess (toxic dose) GSH stores deplete and NAPQI accumulates. D. qRT-PCR for CYP2E1 shows increase in gene 
expression upon both DAC and DAC + paracetamol treatments in DAC-sensitive VU40T cells but not in DAC-resistant SCC040. The 96h treatments were performed as 
indicated and the results are shown normalized to the cDNA concentration. E. CYP2E1 protein levels in VU40T and SCC040 cells also show increase in VU40T cells 
only. The graph represents the data from three experiments normalized to Lamin A/C. F. Glutathione (GSH) levels are reduced significantly in cells treated with DAC 
+ paracetamol as compared to DAC alone. VU40T cells were treated for 96h with DAC, paracetamol or both and the results were normalized to cell viability. 1 mM 
paracetamol was used as a positive control representing toxic concentrations. G. NAC rescue restores cell viability in cells treated with both DAC and DAC +
paracetamol. VU40T cells were pre-treated for 48h with 2.5 mM NAC followed by 96h of DAC, paracetamol or combined treatments (right panel) and cell viability 
was assessed in comparison to control without NAC (left panel). H. Combined treatment significantly enhances oxidative stress when compared to DAC alone; a 
paracetamol specific effect, not observed in co-treatment with valdecoxib. Levels of intracellular ROS (DCFDA staining and FACS) in VU40T cells treated for 72h as 
indicated. Upper figure: representative FACS profile; lower graph: geometric mean normalized to vehicle control. I. The exacerbation of oxidative stress in combined 
treatment was also detected by increased levels of mitochondrial superoxide (MitoSOX Red staining) assessed as in (H). J. Gene expression changes of direct and 
known responders to oxidative stress were extracted from the VU40T RNA-seq data set and show common down-regulation following DAC and DAC + paracetamol 
treatments. They are represented as heatmap of log2 fold change values after indicated treatments. K. Genes implicated in maintaining intracellular cysteine pools 
(uptake of cystine by SLC7A11 or cysteine by SLC1A4) and in thioredoxin reductase system (TXN/TXNRD) are also down-regulated by DAC and DAC + paracetamol 
treatment (shown as in (J)). L. Schematic of proposed mechanism underlying DAC-paracetamol synergy: mimicry of paracetamol overdose through DAC-induced up- 
regulation of CYP2E1, which in the presence of paracetamol leads to GSH depletion and exacerbation of oxidative stress. The effects of DAC are shown in red and 
paracetamol contribution – in blue. M. Drug Set Enrichment Analysis was used to identify the mechanisms of action shared by DAC + paracetamol combination and 
compared to DAC + valdecoxib and DAC alone. Log10 p-values for selected pathways of interest (KEGG or GO BP genesets) are shown as heatmap. N. Disease/ 
Progression-free survival curves for 392 HNSCC patients with data available in TCGA provisional cohort with or without upregulation of genes (z-score ≥2.0) 
implicated in pathways behind DAC-paracetamol drug interaction (for gene sets see Supplementary Methods). Kaplan Meier Estimates were plotted using cBioPortal. 
Left: Up-regulation of genes involved in COX-2-PGE2 pathway correlates with decreased survival. Middle: A negative effect on patients’ survival is observed when 
genes involved in glutathione synthesis are up-regulated, in agreement with a proposed scenario wherein maintaining GSH stores is required for cancer cell survival. 
Right: A poorer survival is observed when genes involved in thioredoxin responses are up-regulated, enabling cellular adaptation to oxidative stress and protection 
from oxidative damage. Unless stated otherwise all treatments were for 96h with 500 nM DAC and 132.2 μM paracetamol, n = 3 for A-B, D-F, H–I and n = 4 for G. In 
A: a mixed -effect analysis with Dunnett’s correction was used to compare DAC to DAC + Vald and DAC + Ibup samples. In B, D–F: One-Way ANOVA with Dunnett’s 
correction was used to compare treatments with Ctrl. In D and F: a separate paired two-tailed t-test was used to compare DAC to DAC + paracetamol. In G: for each 
group (+vehicle, +NAC) a matched One-Way ANOVA with Dunnett’s was used to compare treatments with the respective Ctrl; additionally, a paired two-tailed t-test 
was used to compare Ctrl with NAC. In H–I: a matched One-Way ANOVA with Dunnett’s correction was used to compare all groups to Ctrl; a separate ANOVA was 
used to compare DAC to DAC + Para and DAC + Vald. Values are displayed as means ± SEM. Only significant p values are shown. (For interpretation of the ref-
erences to colour in this figure legend, the reader is referred to the Web version of this article.) 
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due to a very strong reaction to DAC alone at 0.4 mg/kg, we were unable 
to detect a statistically significant decrease in tumour size upon the 
addition of paracetamol. Therefore further investigations, using lower 
DAC dose from the start of treatment, are needed to confirm the benefits 
of combined treatment in vivo. 
3.8. Synergistic effects of DAC + paracetamol co-treatment are also 
observed in AML cell lines 
DAC currently has EMA approval for the treatment of AML [6]. 
Therefore, combined treatment of DAC + paracetamol was tested in two 
AML cell lines, SKM-1 and HL-60, and the drugs were found to work 
synergistically in both (Fig. 6A–C). The combined effect was even more 
apparent when the DAC treatment regimen used in AML patients was 
mimicked [28] (72h treatment, 21 days withdrawal, four cycles, 
Fig. 6D); by the fourth cycle the cells were still responding to combined 
treatment while becoming resistant to DAC alone (Fig. 6D). 
Similar to HNSCC cells, DAC treatment up-regulated PTGS2 and 
PGE2 receptors’ expression in both AML cell lines, and CYP2E1 expres-
sion in SKM-1 cells (Fig. 6E, Supplementary Fig. S8A). Ultimately, DAC 
increased ROS and mitochondrial superoxide production in these cells 
and this was significantly enhanced by the addition of paracetamol, but 
not valdecoxib (Fig. 6F–G). 
Furthermore, combined treatment did not add to the cell death 
caused by DAC alone (Fig. 6H) and resulted only in a slight increase in 
number of cells retained in S phase when compared to DAC alone 
(Fig. 6I). A change towards myelocyte morphology (increased cytoplasm 
and vacuoles’ numbers) was most apparent after DAC + paracetamol 
combined treatment (Fig. 6J), although the expression of myeloid dif-
ferentiation marker CD11b (ITGAM) was similarly up-regulated upon 
DAC and combined treatments (Supplementary Fig. S8B). These data 
indicate that DAC-paracetamol synergy and the effect it has on oxidative 
stress could be applicable to blood malignancies, where DAC is an 
accepted therapeutic option. 5-azacitidine (AZA) is another DNA 
methylation inhibitor approved in the treatment of AML and myelo-
dysplastic syndrome (MDS) [37,38]. Despite both drugs acting by 
replacing cytosines in the DNA, their effects on transcription and 
metabolism differ significantly [39] which is believed to be caused by 
5-azacitidine, but not DAC, being preferentially incorporated into RNA 
[2,39]. Here, we show that paracetamol has no effect on 5-azacitidine 
treatment in either SKM-1 or HL-60 cells (Fig. 6K). A DSEA investiga-
tion indicated disparate impact of 5-azacytidine and paracetamol on 
keratinocyte differentiation, cyclooxygenase and P450 metabolism 
pathways in comparison to DAC and paracetamol (Fig. 6L). 
Therefore, the synergistic effect of paracetamol is specific to co- 
treatment with DAC. 
4. Discussion 
The search for new drugs to improve the survival rate of HNSCC is 
ongoing. Our results using four HNSCC cell lines and an in vivo mouse 
model show that DAC alone has therapeutic potential in HNSCC. How-
ever, the response is variable, as has been observed for other solid tu-
mours [8] and patient stratification using predictive biomarkers will be 
necessary to identify the DAC-responders. The results shown here 
demonstrate that DAC sensitivity is primarily dependent upon the drug’s 
ability to demethylate DNA, and therefore likely due to incorporation, 
activation or retention of the drug, as suggested previously [40,41]. 
Furthermore, an initial response to DAC was a prerequisite for synergy 
with paracetamol, hence the co-treatment is dependent upon the DNA 
demethylating capacity of DAC. 
Paracetamol is routinely prescribed as an analgesic, however so far it 
has not been considered whether its use may influence the efficacy of 
chemotherapy regimens. Our study demonstrates that paracetamol can 
enhance the anti-tumour activity of DAC with two main translational 
impacts. Adding paracetamol to DAC treatment could significantly 
lower the DAC dose needed to achieve therapeutic effects, potentially 
reducing DNA damage-related side effects and ultimately broadening 
DAC application. It also highlights that uncontrolled use of paracetamol 
during cancer therapies and clinical trials could affect the outcomes and 
interpretation of the results. Hence, further studies are required to look 
at the impact of supportive care medication in oncology. 
In this report we identified key mechanisms within the AA meta-
bolism pathway that could underlie the synergy between DAC and 
paracetamol (Fig. 7). Both our data and analysis of public databases 
point towards DAC explicitly upregulating COX-2-PGE2 pathway, PTGS2 
in particular, potentially providing cancer cells with survival advantage. 
However, it remains to be established whether this is a direct result of 
DNA demethylation or is rather due to indirect mechanisms (e.g. 
response to dsRNA, cytokines or growth factors). 
Surprisingly, the synergistic effect observed for paracetamol could 
not be reproduced using other COX-2 inhibitors. Although it is possible 
some tumour cells could still be affected by the suppression of COX-2- 
PGE2 pathway, the data indicate an alternative and paracetamol-specific 
mechanism; DAC-induced mimicry of paracetamol overdose, leading to 
GSH depletion and exacerbated oxidative stress, both of which have the 
potential to restrict tumour growth and improve patient survival [36]. 
The synergistic effect was also specific to DAC and not applicable to the 
structurally similar DNA methylation inhibitor, 5-azacitidine. The 
mechanisms described in this study likely explain the specificity of 
DAC-paracetamol drug interaction. 
Response to DAC has a profound effect on the transcriptional pro-
gramme in HNSCC cells and is dominated by activation of type I 
Fig. 5. In vivo potential of DAC + paracetamol combined treatment in HNSCC. A-B. DAC-paracetamol synergy was confirmed in HNSCC FaDu cells prior to their use 
in mice xenografts (shown as in Fig. 1E–G); cell viability was assessed after treatment with fixed Cmax titrations of the drugs (A). The resulting combination index (CI) 
is below 1 for all concentrations, indicating synergy (B). C. Gene expression of PTGS2, its receptors (PTGER1 and PTGER2) and CYP2E1 increase in FaDu cells 
following DAC and DAC + paracetamol treatments, in agreement with the data presented in Figs. 3 and 4. qRT-PCR data are shown relative to ACTB. D. Glutathione 
(GSH) levels are reduced significantly in cells treated with DAC + paracetamol as compared to DAC alone. FaDu cells were treated for 96h with DAC, paracetamol or 
both and the results were normalized to cell density. 1 mM paracetamol was used as a positive control representing toxic concentrations. E. Combined treatment 
increases the levels of ROS (left) and, significantly, mitochondrial superoxide (right) when compared to DAC alone; a paracetamol specific effect, not observed in co- 
treatment with valdecoxib. Levels of intracellular ROS (DCFDA staining and FACS) and mitochondrial superoxide (MitoSOX Red staining) assessed as in (Fig. 4H–I).F. 
The expression of markers of the basal cell layer (TP63 and KRT5) and differentiated keratinocytes (IVL) upon DAC and paracetamol treatment in FaDu cells. qRT- 
PCR results are shown as normalized to ACTB. G. Tumour growth of FaDu cells engrafted into NSG mice (Day 1, red arrow) and treated as indicated (black arrows) 
suggests the efficacy of DAC treatment is enhanced in vivo by co-treatment with paracetamol. * indicates mouse culling due to disease progression. H. Days to reach 
tumour size of 200 mm3 in each treatment. Tumours below 200 mm3 at the end of the experiment are counted as Day 25. I. qRT-PCR performed on RNA extracted 
from tumour tissues shows DAC-induced up-regulation of PTGS2 and CYP2E1, confirming the in vitro results. Results are normalized to ACTB. J. qRT-PCR performed 
on RNA extracted from tumour tissues shows TP63 and KRT5 are down-regulated by DAC, with stronger effect observed in combined treatment in agreement with the 
in vitro data. Results are normalized to ACTB. In A-F n = 3. In G-H: Ctrl (n = 6), paracetamol (n = 6), DAC (n = 5), DAC + paracetamol (n = 6). In I-J: Ctrl (n = 6), 
paracetamol (n = 6), DAC (n = 4), DAC + paracetamol (n = 5). C,D,F: for each group a matched One-Way ANOVA with Dunnett’s was used to compare treatments 
with Ctrls; additionally, a paired two-tailed t-test was used to compare DAC with DAC + Para. In E: a matched One-Way ANOVA with Dunnett’s correction was used 
to compare all groups to Ctrl; a separate ANOVA was used to compare DAC to DAC + Para and DAC + Vald. In H-J: a non-matched One-Way ANOVA with Dunnett’s 
correction was used to compare treatments with control. To compare DAC and DAC + Para an unpaired two-tailed t-test was used. Values are displayed as means ±
SEM. Only significant p values are shown. 
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interferon and anti-viral pathways, agreeing with recent reports on the 
role of ‘viral mimicry’ in cancer treatment with DNA demethylating 
agents [3,4]. These effects are maintained but not increased by com-
bined treatment and, since the immune response is currently thought to 
be an important part of response to DAC, it would be beneficial to test 
the synergy between DAC and paracetamol in an immune competent in 
vivo model. 
Instead, the addition of paracetamol to DAC treatment led to a 
decrease in DNA, RNA and protein metabolism, together with reduced 
proliferation and enhanced differentiation. Notably, ‘keratinocyte dif-
ferentiation’ emerged in the DSEA as one of the most enriched terms 
affected specifically by DAC-paracetamol combination. Further experi-
ments are required to establish the exact mechanisms leading to the 
changes in cell proliferation and differentiation upon combined treat-
ment. One possibility involves the effects of AA metabolism and ROS on 
PI3K/Akt and MAPK pathways, the main proliferation drivers in HNSCC 
[42]. 
This study demonstrates that the commonly used drug, paracetamol, 
available as over-the-counter medicine and often self-medicated by pa-
tients, can change the cancer cell response to a chemotherapeutic. 
Therefore, considering the mechanisms described here, paracetamol 
interaction with other drugs, especially chemotherapeutics, should be 
taken into consideration. This manuscript provides a solid rationale for 
the controlled use of paracetamol in AML, where DAC treatment has 
already been approved and suggests efficacy may also be applicable to 
HNSCC. Since paracetamol is a very cheap and relatively safe drug, it 
could be added to treatment with minimal cost but considerable trans-
lational impact. 
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Fig. 6. Potential of DAC-paracetamol combined treatment in AML. A-C. DAC-paracetamol synergy was established in AML cell lines, SKM-1 (A) and HL-60 (B), 
treated as indicated for 72h. Cell viability data were used to calculate combination index (CI) which confirmed synergy in both (C). D. Long term effects of DAC and 
DAC-paracetamol combined treatment on growth rates were assessed in SKM-1 (left) and HL-60 (right) cells over four treatment cycles (C1–C4, 72h treatment as 
indicated followed by 21-day withdrawal), indicating paracetamol could prolong the efficacy of DAC treatment. Vehicle and paracetamol controls are shown for the 
first 10 days. E. Gene expression of PTGS2, its receptors (PTGER1, PTGER2 and PTGER3) and CYP2E1 increase in SKM-1 cells following DAC and DAC + paracetamol 
treatments in agreement with the HNSCC data. qRT-PCR data are shown normalized against ACTB. F. Levels of intracellular ROS measured by DCFDA staining and 
FACS in SKM-1 cells treated for 72h with indicated drugs and their combinations. Vald, 10 μM valdecoxib. The ROS levels are increased in DAC + paracetamol, but 
not DAC + valdecoxib, when compared to DAC alone in agreement with the HNSCC data. The results are shown as geometric mean normalized to vehicle control. G. 
Levels of mitochondrial superoxide assessed by MitoSOX Red staining and FACS in SKM-1 cells as in (F) also show that only the addition of paracetamol exacerbates 
oxidative stress in DAC-treated cells. H. Proportion of SKM-1 cells undergoing cell death was assessed by FACS following Annexin V and PI staining. The DAC-induced 
increase in cell death is not additionally enhanced by addition of paracetamol. I. Cell cycle distribution of SKM-1 cells following 72h of indicated treatments. J. 
Giemsa-Jenner staining in SKM-1 cells reveals enhanced features of myeloid differentiation after combined treatment, increased cytoplasm with vacuole formation 
(black arrow). Upper: 100x magnification; lower: image zoomed to approximately one cell. K. Cell viability experiments in SKM-1(upper graph) and HL-60 (lower 
graph) cells after titrations of the Cmax of AZA (3 μM), paracetamol (132.2 μM) or both for 72h. Results indicate that paracetamol does not sensitize cells to 5-aza-
citidine treatment. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) L. DSEA was used to 
identify the differences in the mechanisms of action between DAC and azacitidine (AZA) and their combinations with paracetamol. While ‘Keratinocyte differen-
tiation’ and ‘TP63 pathway’ are among the most enriched terms for DAC + paracetamol combination, they are not enhanced by AZA + paracetamol. In addition, AZA 
does not activate the cyclooxygenase pathway to the same extend as DAC; and cytochrome P450 metabolism term is only enhanced by addition of paracetamol to 
DAC but not AZA. Log10 p-values for selected pathways of interest are shown as heatmap. Unless stated otherwise all treatments were for 72h with 500 nM DAC and 
132.2 μM paracetamol and n = 3. In E-G: a matched One-Way ANOVA with Dunnett’s correction was applied to compare treatments with control; in F-G a separate 
ANOVA was used to compare DAC to DAC + Para and DAC + Vald. In H–I: for each group a matched Two-Way ANOVA with Dunnett’s was performed to compare 
treatments with control; a separate Two-Way ANOVA with Sidak’s was used to compare DAC with DAC + Para. Values are displayed as means ± SEM. Only sig-
nificant p values are shown. 
Fig. 7. Mechanisms underlying DAC-paracetamol interaction. Arachidonic acid (AA) is metabolized to eicosanoids through COX, LOX, and cytochrome P450 
monooxygenase pathways. In addition to DAC limiting cancer cell growth through either activation of tumour suppressor genes (TSGs) or viral mimicry (1), it 
inadvertently activates COX-2 PGE2 pathway (2), which is contradicted by paracetamol. DAC also upregulates CYP2E1 which, in the presence of paracetamol, leads 
to glutathione depletion and ROS accumulation, both enhanced by combined treatment (3). Our preliminary data also indicate that DAC potentially downregulates 
transcription of genes involved in antioxidant and thioredoxin responses, preventing cancer cells from developing adaptation to oxidative stress and protection from 
oxidative damage. In addition, GSH depletion has the potential to limit the production of LOX pathway metabolites dependent on GSH transferases. 
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